Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Buchdunger

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Journal of the National Cancer Institute|January 29, 1999
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitorP le Coutre, L Mologni, L Cleris, et al.
Medicinal Research Reviews|October 19, 2001
Tyrosine kinase inhibitors: from rational design to clinical trialsP Traxler, G Bold, E Buchdunger, et al.
Journal of Medicinal Chemistry|June 23, 1995
[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinaseP Traxler, U Trinks, E Buchdunger, et al.
British Journal of Haematology|March 6, 1998
Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factorsT Jonuleit, C Peschel, R Schwab, et al.
International Journal of Cancer|May 21, 1999
Author errataN Lydon, H Mett, M Mueller, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2003
Imatinib: a selective tyrosine kinase inhibitorP W Manley, S W Cowan-Jacob, E Buchdunger, et al.
Nature Medicine|May 1, 1996
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsB J Druker, S Tamura, E Buchdunger, et al.
Blood|January 7, 1998
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteinsM Carroll, S Ohno-Jones, S Tamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1995
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activityE Buchdunger, H Mett, U Trinks, et al.
International Journal of Cancer|April 9, 1998
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivoN B Lydon, H Mett, M Mueller, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Journal of the National Cancer Institute|January 29, 1999
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitorP le Coutre, L Mologni, L Cleris, et al.
Medicinal Research Reviews|October 19, 2001
Tyrosine kinase inhibitors: from rational design to clinical trialsP Traxler, G Bold, E Buchdunger, et al.
Journal of Medicinal Chemistry|June 23, 1995
[(Alkylamino)methyl]acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinaseP Traxler, U Trinks, E Buchdunger, et al.
British Journal of Haematology|March 6, 1998
Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factorsT Jonuleit, C Peschel, R Schwab, et al.
International Journal of Cancer|May 21, 1999
Author errataN Lydon, H Mett, M Mueller, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2003
Imatinib: a selective tyrosine kinase inhibitorP W Manley, S W Cowan-Jacob, E Buchdunger, et al.
Nature Medicine|May 1, 1996
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsB J Druker, S Tamura, E Buchdunger, et al.
Blood|January 7, 1998
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteinsM Carroll, S Ohno-Jones, S Tamura, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1995
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activityE Buchdunger, H Mett, U Trinks, et al.
International Journal of Cancer|April 9, 1998
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivoN B Lydon, H Mett, M Mueller, et al.
Pageof 5